CDCorleone S. Delaveris

Corleone S. Delaveris

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Corleone S. Delaveris has a total of 71 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Cellular Consequences, Citrullination Substrates, and Antigenicity of Targeting PAD4 to Cell Surfaces

    by Sophie Kong, Trenton M. Peters-Clarke, Corleone S. Delaveris, Paul Phojanakong, Veronica Steri, James A. Wells

    Protein arginine deiminase-4 (PAD4) catalyzes hydrolysis of arginine to citrulline in proteins that promote widespread cellular changes that can induce innate immunity and promote cancer. Hyperactivity of PAD4 leads to a form of cell death called NETosis, releasing PAD4 to the extracellular space to promote various autoimmune diseases through the generation of anticitrulline protein antibodies (ACPAs). Little is known about the specific citrullinated substrates that lead to autoimmunity, but there is growing evidence that PAD4 is localized to the cell surface in response to inflammation. Here, we characterize the cellular consequences of exogenous PAD4, showing that it induces morphological changes that increase cell migration, a hallmark of cancer. We then devised a robust proteomics approach to identify PAD4 substrates. We identified ∼ 3000 citrullinated peptides from 1300 proteins upon exogenous addition of PAD4 both inside and outside of cells. This extracellular set can be further augmented by targeting PAD4 to cancer cells using a HER2 binding protein conjugate. Finally, we studied how citrullinated cells can induce a humoral response in vivo to produce ACPAs. We believe these studies further our understanding of cellular consequences of extracellular PAD4 and identify new PAD4 substrates that are potential neoepitopes for ACPA generation.

  • Top Cited Papers

    Autophagolysosomal exocytosis inverts Src kinase onto the cell surface in cancer

    by Corleone S. Delaveris, Rita P. Loudermilk, Apurva Pandey, Soumya G. Remesh, Trenton M. Peters-Clarke, Snehal D. Ganjave, William J. N. Dougherty, Henry M. Delavan, Chunyue Wang, Jesse Ling, et al.

    Overexpression of the proto-oncogene Src is common to a wide variety of cancers. In this work, we found that Src is noncanonically translocated and inverted onto the cell surface in cancer, both in vitro and in vivo. We identified autophagolysosomal exocytosis (ALE) as a secretory mechanism prominent in cancer cell lines. Src represents the prototypical example of a family of membrane-anchored proteins that are transported by this process. Furthermore, this extracellular membrane–associated Src (eSrc) was found in primary tumors, and anti-Src antibody-based therapies mediated tumor cell killing in cell culture systems and in mouse xenograft models. Thus, intracellular N -myristoylated proteins, prototypically Src, can be topologically inverted onto the cell surface in cancer and targeted with antibody therapeutics.


  • Chemoproteomics reveals immunogenic and tumor-associated cell surface substrates of ectokinase CK2α

    by Corleone S. Delaveris, Sophie Kong, Jeff Glasgow, Rita P. Loudermilk, Lisa L. Kirkemo, Fangzhu Zhao, Fernando Salangsang, Paul Phojanakong, Juan Antonio Camara Serrano, Veronica Steri, et al.


  • Open Access

    Chemoproteomics reveals immunogenic and tumor-associated cell surface substrates of ectokinase CK2α

    by Corleone S. Delaveris, Sophie Kong, Jeff Glasgow, Rita P. Loudermilk, Lisa L. Kirkemo, Fangzhu Zhao, Fernando Salangsang, Paul Phojanakong, Juan Antonio Camara Serrano, Veronica Steri, et al.

    Summary: New epitopes for immune recognition provide the basis of anticancer immunity. Due to the high concentration of extracellular adenosine triphosphate in the tumor microenvironment, we hypothesized that extracellular kinases (ectokinases) could have dysregulated activity and introduce aberrant phosphorylation sites on cell surface proteins. We engineered a cell-tethered version of the extracellular kinase CK2α, demonstrated it was active on cells under tumor-relevant conditions, and profiled its substrate scope using a chemoproteomic workflow. We then demonstrated that mice developed polyreactive antisera in response to syngeneic tumor cells that had been subjected to surface hyperphosphorylation with CK2α. Interestingly, these mice developed B cell and CD4+ T cell responses in response to these antigens but failed to develop a CD8+ T cell response. This work provides a workflow for probing the extracellular phosphoproteome and demonstrates that extracellular phosphoproteins are immunogenic even in a syngeneic system.

  • Open Access

    Microglia Mediate Contact-Independent Neuronal Network Remodeling via Secreted Neuraminidase-3 Associated with Extracellular Vesicles

    by Corleone S. Delaveris, Catherine L. Wang, Nicholas M. Riley, Sherry Li, Rishikesh U. Kulkarni, Carolyn R. Bertozzi

    Neurons communicate with each other through electrochemical transmission at synapses. Microglia, the resident immune cells of the central nervous system, modulate this communication through a variety of contact-dependent and -independent means. Microglial secretion of active sialidase enzymes upon exposure to inflammatory stimuli is one unexplored mechanism of modulation. Recent work from our lab showed that treatment of neurons with bacterial sialidases disrupts neuronal network connectivity. Here, we find that activated microglia secrete neuraminidase-3 (Neu3) associated with fusogenic extracellular vesicles. Furthermore, we show that Neu3 mediates contact-independent disruption of neuronal network synchronicity through neuronal glycocalyx remodeling. We observe that NEU3 is transcriptionally upregulated upon exposure to inflammatory stimuli and that a genetic knockout of NEU3 abrogates the sialidase activity of inflammatory microglial secretions. Moreover, we demonstrate that Neu3 is associated with a subpopulation of extracellular vesicles, possibly exosomes, that are secreted by microglia upon inflammatory insult. Finally, we demonstrate that Neu3 is necessary and sufficient to both desialylate neurons and decrease neuronal network connectivity. These results implicate Neu3 in remodeling of the glycocalyx leading to aberrant network-level activity of neurons, with implications in neuroinflammatory diseases such as Parkinson's disease and Alzheimer's disease.


  • Open Access

    Microglia mediate contact-independent neuronal pruning via secreted Neuraminidase-3 associated with extracellular vesicles

    by Corleone S. Delaveris, Catherine L. Wang, Nicholas M. Riley, Sherry Li, Rishikesh U. Kulkarni, Carolyn R. Bertozzi

    Neurons communicate with each other through electrochemical transmission at synapses. Microglia, the resident immune cells of the central nervous system, can prune these synapses through a variety of contact-dependent and -independent means. Microglial secretion of active sialidase enzymes upon exposure to inflammatory stimuli is one unexplored mechanism of pruning. Recent work from our lab showed that treatment of neurons with bacterial sialidases disrupts neuronal network connectivity. Here, we find that activated microglia secrete Neuraminidase-3 (Neu3) associated with fusogenic extracellular vesicles. Furthermore, we show Neu3 mediates contact-independent pruning of neurons and subsequent disruption of neuronal networks through neuronal glycocalyx remodeling. We observe that NEU3 is transcriptionally upregulated upon exposure to inflammatory stimuli, and that a genetic knock-out of NEU3 abrogates the sialidase activity of inflammatory microglial secretions. Moreover, we demonstrate that Neu3 is associated with a subpopulation of extracellular vesicles, possibly exosomes, that are secreted by microglia upon inflammatory insult. Finally, we demonstrate that Neu3 is both necessary and sufficient to both desialylate neurons and decrease neuronal network connectivity. These results implicate Neu3 in remodeling of the glycocalyx leading to aberrant network-level activity of neurons, with implications in neuroinflammatory diseases such as Parkinson’s disease and Alzheimer’s disease. Graphical Neuroinflammation induces secretion of the sialidase Neu3 via extracellular vesicles from microglia that prune neuronal synapses and disrupt neuronal communication.


  • Open Access

    MYC-driven synthesis of Siglec ligands is a glycoimmune checkpoint

    by Benjamin A. H. Smith, Anja Deutzmann, Kristina M. Correa, Corleone S. Delaveris, Renumathy Dhanasekaran, Christopher G. Dove, Delaney K. Sullivan, Simon Wisnovsky, Jessica C. Stark, John V. Pluvinage, et al.

    The Siglecs (sialic acid-binding immunoglobulin-like lectins) are glycoimmune checkpoint receptors that suppress immune cell activation upon engagement of cognate sialoglycan ligands. The cellular drivers underlying Siglec ligand production on cancer cells are poorly understood. We find the MYC oncogene causally regulates Siglec ligand production to enable tumor immune evasion. A combination of glycomics and RNA-sequencing of mouse tumors revealed the MYC oncogene controls expression of the sialyltransferase St6galnac4 and induces a glycan known as disialyl-T. Using in vivo models and primary human leukemias, we find that disialyl-T functions as a “don’t eat me” signal by engaging macrophage Siglec-E in mice or the human ortholog Siglec-7, thereby preventing cancer cell clearance. Combined high expression of MYC and ST6GALNAC4 identifies patients with high-risk cancers and reduced tumor myeloid infiltration. MYC therefore regulates glycosylation to enable tumor immune evasion. We conclude that disialyl-T is a glycoimmune checkpoint ligand. Thus, disialyl-T is a candidate for antibody-based checkpoint blockade, and the disialyl-T synthase ST6GALNAC4 is a potential enzyme target for small molecule-mediated immune therapy.


  • Open Access

    Synthetic Siglec-9 Agonists Inhibit Neutrophil Activation Associated with COVID-19

    by Corleone S. Delaveris, Aaron J. Wilk, Nicholas M. Riley, Jessica C. Stark, Samuel S. Yang, Angela J. Rogers, Thanmayi Ranganath, Kari C. Nadeau, The Stanford Covid-19 Biobank, Catherine A. Blish, et al.

    Severe cases of coronavirus disease 2019 (COVID-19), caused by infection with SARS-CoV-2, are characterized by a hyperinflammatory immune response that leads to numerous complications. Production of proinflammatory neutrophil extracellular traps (NETs) has been suggested to be a key factor in inducing a hyperinflammatory signaling cascade, allegedly causing both pulmonary tissue damage and peripheral inflammation. Accordingly, therapeutic blockage of neutrophil activation and NETosis, the cell death pathway accompanying NET formation, could limit respiratory damage and death from severe COVID-19. Here, we demonstrate that synthetic glycopolymers that activate signaling of the neutrophil checkpoint receptor Siglec-9 suppress NETosis induced by agonists of viral toll-like receptors (TLRs) and plasma from patients with severe COVID-19. Thus, Siglec-9 agonism is a promising therapeutic strategy to curb neutrophilic hyperinflammation in COVID-19.


  • Modulation of immune cell reactivity with cis -binding Siglec agonists

    by Corleone S. Delaveris, Shannon H. Chiu, Nicholas M. Riley, Carolyn R. Bertozzi

    Significance: Cells are covered in a dense forest of sugars. The abundance of specific sugar structures can influence immune cell activation, in part through a class of sugar-binding immune receptors known as Siglecs. However, the effects of Siglecs engaged by cis ligands are poorly understood. Thus, to elucidate these interactions, in this work we developed biomimetic structures of native glycoproteins bearing selective Siglec ligands. We demonstrate that these structures bind Siglec receptors and stimulate Siglec signaling when used as membrane-tethered cis ligands but that soluble analogs lacking a membrane-tethering lipid do not. These results present cis ligands as a way to target Siglecs in inflammatory diseases.


  • Open Access

    Modulation of Immune Cell Reactivity with Cis-Binding Siglec Agonist

    by Corleone Delaveris, Shannon Chiu, Nicholas Riley, Carolyn Bertozzi

    Primary inflammatory pathologies caused by phagocytes lead to numerous debilitating conditions, including chronic pain and blindness due to age-related macular degeneration. Many members of the sialic acid-binding immunoglobulin-like lectin (Siglec) family are immunoinhibitory receptors whose agonism is an attractive approach to for anti-inflammatory therapy. Here, we show that synthetic lipid-conjugated glycopolypeptides can insert into cell membranes and engage Siglec receptors in cis, leading to inhibitory signaling. Specifically, we construct a cis-binding agonist of Siglec-9 and show that it modulates MAPK signaling in reporter cell lines, immortalized macrophage and microglial cell lines, and primary human macrophages. These cis-binding agonists of Siglecs present a new modality for therapeutic suppression of immune cell reactivity.